Product Description
Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
AI Product Description
*The following content is generated by AI and is for reference only.
Sorafenib, commercially known as Nexavar, is a potent small-molecule multikinase inhibitor widely utilized in oncology for the treatment of advanced malignancies. Its chemical identity is defined by the molecular formula C21H16ClF3N4O3 and the CAS registry number 284461-73-0. Structurally, it belongs to the class of pyridine derivatives featuring a chloro-fluoro-benzyl group, which is crucial for its specific binding affinity to various intracellular signaling pathways.
The primary clinical application of Sorafenib targets hepatocellular carcinoma (HCC) in patients with unresectable disease or metastatic renal cell carcinoma (RCC). It functions through a dual mechanism of action: inhibiting tumor cell proliferation and suppressing angiogenesis. Specifically, Sorafenib blocks the activity of serine/threonine kinases such as RAF-1, B-Raf, and c-KIT, thereby disrupting the MAPK/ERK pathway essential for cancer cell growth. Simultaneously, it inhibits receptor tyrosine kinases including VEGFR-2, VEGFR-3, and PDGFR-beta, effectively cutting off the blood supply required for tumor expansion. This anti-angiogenic effect starves the tumor of nutrients and oxygen, leading to regression.
Administered orally as tablets, Sorafenib offers a convenient treatment regimen compared to traditional intravenous chemotherapies. While generally well-tolerated, common adverse effects include hand-foot skin reaction, diarrhea, fatigue, and hypertension, necessitating careful patient monitoring. Extensive clinical trials have demonstrated that Sorafenib significantly prolongs overall survival in HCC patients, marking a pivotal advancement in targeted cancer therapy since its approval. Ongoing research continues to explore its efficacy in combination therapies for other solid tumors, including thyroid cancer and pancreatic cancer, aiming to expand its therapeutic horizon. As a cornerstone of modern precision medicine, Sorafenib remains a critical tool in the fight against aggressive cancers, offering hope where conventional treatments have failed. Its unique pharmacological profile underscores the importance of kinase inhibition in managing complex oncological conditions.